Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...

Merger Completion: On August 15, 2024, Silexion completed its business combination with Moringa Acquisition Corp, becoming a publicly traded company on Nasdaq under the ticker “SLXN.” This strategic ...

Myotonic Dystrophy Type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely affects multiple organs ...

New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in agriculture and horticulture ...

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 -U.S. Food and ...

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators ...

Welcome to Maravai LifeSciences fourth quarter 2024 results earnings call. At this time, all participants are in a ...

Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...

It's Inno Madness time! Inno Madness is our friendly, bracket-style challenge where readers vote to advance companies based ...

A growing body of work suggests that cell metabolism — the chemical reactions that provide energy and building materials — ...

This summit offers valuable insights into key issues like productivity, decarbonisation, workforce development, and safety, ...

SCIENTISTS have found a pill that offers ‘100 per cent protection’ against Ebola – sparking hopes of eradicating the deadly ...